Anti-Human ICAM-1 (CD54) (Clone R6-5-D6) – Recombinant in vivo Functional Grade

EBV transformed lymphoblast cell line

This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Liquid

Recombinant antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 – 8° C Wet Ice

R6-5-D6 activity is directed against human ICAM-1 (CD54)

ICAM-1 or CD54 is a glycoprotein found on the surface of endothelial and epithelial cells during inflammation. It plays a significant role in the interactions between cells and immune responses. ICAM-1 helps in the adhesion and movement of leukocytes expressing activated LFA-1 (CD11a/CD18) and Mac-1 (CD11b/CD18)¹.

Studies suggest that sICAM-1 (soluble ICAM-1) can bind to various non-integrin ligands, such as CD43/sialophorin, fibrinogen, hyaluronan, rhinoviruses, and Plasmodium falciparum-infected erythrocytes. In addition, sICAM-1 can be used as an indicator of vascular endothelial cell activation or damage by promoting angiogenesis².

Increased levels of sICAM-1 are associated with various diseases such as chronic coronary heart disease, type 2 diabetes, organ transplant dysfunction, oxidant stress, and certain malignancies^3-5.

Clone R6-5-D6, is a monoclonal antibody that has been used in research to study the expression and function of ICAM-1 in different contexts, such as viral infections, solid tumors, and graft-versus-host disease. The antibody has shown efficacy in inhibiting infection, characterizing ICAM-1 expression, and enhancing immune responses^6-9. It also inhibits CD54 interaction with leukocytes, thereby reducing inflammation^10,11.

CD54 is typically expressed on non-hematopoietic cells such as endothelial cells, thymic epithelial cells, fibroblasts, macrophages, T-lymphoblasts, germinal center B cells and dendritic cells.

CD40

1. Bullard DC, Hu X, Crawford D, McDonald K, Ramos TN, Barnum SR. Eur J Immunol. 2014;44(4):1194-1199.
2. Gho YS, Kleinman HK, Sosne G. Cancer Res. 1999;59(20):5128-5132.
3. Haim M, Tanne D, Boyko V, et al. J Am Coll Cardiol. 2002;39(7):1133-1138.
4. Al-Heety QQ, Kasabri V, Akour A, Naffa R, Abu Rkhaya S. Ther Adv Endocrinol Metab. 2018;9(10):303-310.
5. Hoogeveen RC, Ballantyne CM, Bang H, et al. Diabetologia. 2007;50(1):36-42.
6. Chen Y, Zhao C, Liu G, et al. Sheng Wu Gong Cheng Xue Bao. 2018;34(12):2016-2024.
7. Kobayashi H, Miyano T, Yamataka A, et al. Cardiovasc Surg. 1993;1(5):577-582.
8. Lawson C, Holder AL, Stanford RE, Smith J, Rose ML. Transplantation. 2005;80(2):264-271.
9. Gerbitz A, Ewing P, Olkiewicz K, et al. Transplantation. 2005;79(5):536-542.
10. Gudemez E, Turegun M, Carnevale K, Zins J, Siemionow M. Plast Reconstr Surg. 1999;104(1):161-170.
11. Steidl U, Haas R, Kronenwett R. Ann Hematol. 2000;79(8):414-423.
12. Williams KM, Dotson AL, Otto AR, Kohlmeier JE, Benedict SH. Cell Immunol. 2011;271(2):418-427.
13. Vestweber D, Zeuschner D, Rottner K, Schnoor M. Tissue Barriers. 2013;1(1):e23862.
14. Schnoor M, Lai FPL, Zarbock A, et al. J Exp Med. 2011;208(8):1721-1735.